In short
NNC0194-0499 is an investigational drug being studied for the treatment of various liver conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcohol-related liver disease. This article summarizes the key findings from several clinical trials exploring the safety, effectiveness, and pharmacokinetics of NNC0194-0499 in different patient populations.
At a glance
- Drug Name
- NNC0194-0499
- Conditions Studied
- Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Alcohol-related liver disease
- Administration Method
- Subcutaneous injection
- Dose Ranges
- Various, including 3.0 mg, 9.0 mg, 12 mg, 27 mg, 30 mg, 60 mg, 96 mg, 120 mg
- Study Populations
- Healthy volunteers, Overweight/obese individuals, Patients with liver diseases, Various ethnic groups (Chinese, Japanese, Non-Asian)
- Primary Outcomes
- Safety, Tolerability, Pharmacokinetics
- Secondary Outcomes
- Changes in liver enzymes, lipid profiles, body weight, alcohol use markers
- Combination Therapies
- NNC0194-0499 with semaglutide, NNC0194-0499 with cagrilintide
- Study Durations
- Ranging from single-dose studies to 24-week treatments
What is NNC0194-0499?
NNC0194-0499 is a new investigational medicine being developed by Novo Nordisk for the treatment of liver diseases. It is currently undergoing clinical trials to evaluate its safety and effectiveness. NNC0194-0499 is not yet approved by health authorities for use outside of research studies.
What conditions does NNC0194-0499 treat?
NNC0194-0499 is being investigated for the treatment of several liver conditions:
- Non-alcoholic fatty liver disease (NAFLD): A condition where excess fat builds up in the liver of people who drink little or no alcohol.
- Non-alcoholic steatohepatitis (NASH): A more severe form of NAFLD that includes liver inflammation and damage.
- Alcohol-related liver disease: Liver damage caused by excessive alcohol consumption.
These conditions can lead to serious liver problems if left untreated, including scarring of the liver (cirrhosis) and liver failure.
How is NNC0194-0499 administered?
NNC0194-0499 is given as an injection under the skin (subcutaneous injection). In clinical trials, it has been administered in various ways:
- As a single dose
- Once weekly injections for several weeks
- In combination with other medications
The exact dosing and administration schedule may vary depending on the specific study and condition being treated.
Clinical Trials of NNC0194-0499
Several clinical trials are being conducted to evaluate NNC0194-0499:
- Studies in healthy volunteers to understand how the drug behaves in the body
- Trials in people with various degrees of liver disease
- Research on its effects in people with obesity
- Investigations of its use in combination with other medications
These trials aim to determine the safety, effectiveness, and optimal dosing of NNC0194-0499 for different patient groups.
Potential Side Effects
As NNC0194-0499 is still in the research phase, all of its potential side effects are not yet known. Clinical trials are carefully monitoring for any adverse events (unwanted effects) that may occur. Common measures being tracked include:
- Changes in heart rate and blood pressure
- Effects on liver and kidney function
- Changes in blood tests (e.g., cholesterol levels)
- Injection site reactions
It's important to note that not all participants will experience side effects, and the safety profile of the drug is still being established through ongoing research.
Combination Therapy with Semaglutide
Some studies are investigating the use of NNC0194-0499 in combination with another drug called semaglutide. Semaglutide is an approved medication used to treat type 2 diabetes and obesity. Researchers believe that combining these two drugs may provide better results in treating NASH than either drug alone.
The combination therapy is being studied to see if it can:
- Reduce liver damage
- Improve liver function
- Help with weight loss
- Manage blood sugar levels in people with diabetes
Ongoing Research
NNC0194-0499 is still in the early stages of development. Ongoing and future studies will help determine:
- The most effective dose of the medication
- Long-term safety and effectiveness
- Which patients are most likely to benefit from the treatment
- How it compares to or combines with other liver disease treatments
It's important to note that as an investigational drug, NNC0194-0499 is not currently available for general use. Patients interested in this treatment should speak with their healthcare providers about the possibility of participating in clinical trials.